All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Psoriasis and Psoriatic Arthritis Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Psoriasis and Psoriatic Arthritis Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Psoriasis and Psoriatic Arthritis Hub cannot guarantee the accuracy of translated content. The Psoriasis and Psoriatic Arthritis Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What are the key updates to the GRAPPA guidelines, and how should HCPs be using them?

Jul 3, 2023

The Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Kathleen Gallant, International Federation of Psoriasis Associations (IFPA), Pittsburg, US, and Laura Coates, University of Oxford, Oxford, UK. We asked, What are the key updates to the GRAPPA guidelines, and what is your advice on how HCPs should use them?

What are the key updates to the GRAPPA guidelines, and how should HCPs be using them?

Coates begins by addressing the key updates of the Group of Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) guidelines, focusing on new data gathered around existing therapies, as well as new therapies, such as new mode of action biological drugs/targeted synthetic drugs. Gallant and Coates go on to discuss how the guidance might impact existing treatment regimens and how this differs to previous treatment recommendations. Coates highlights the potential benefits the guideline updates may have, allowing for a more targeted approach when it comes to selecting drugs for individuals and being able to better factor in comorbidities and associated conditions during treatment selection. Coates also touches on the fact that the updates are international recommendations and flexible, enabling them to be applied to the various approvals and healthcare settings in different countries. Finally, Gallant and Coates discuss how patients could talk about treatment options with their HCPs, and touch upon the importance of conversations and shared decision-making around therapeutic choice.


Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox